Search Results

Bone Biologics Corporation announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device.

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion.

Bone Biologics Corporation today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock.

Cantor Fitzgerald analyst Olivia Brayer found supplementary bone mineral density data for Amgen’s obesity candidate MariTide that could point to a potentially greater fracture risk than previously revealed, but some other analysts view the findings as a nonissue.

Bone Biologics Corporation announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share and accompanying warrant.

Bone Biologics Corporation today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.

Bone Biologics Corporation today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.

At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix product to cure common but challenging orthopedic conditions, has potential to replace existing allogeneic bone substitutes to heal fractures